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Abstract
Background Value of information (VOI) is a tool that can
be used to inform decisions concerning additional research
in healthcare. VOI estimates the value of obtaining addi-
tional information and indicates the optimal design for
additional research. Although it is recognized as good
practice in handling uncertainty, it is still hardly used in
decision making in the Netherlands.
Objective This paper aims to examine the potential value
of VOI, barriers and facilitators and the way forward with
the use of VOI in the decision-making process for reim-
bursement of pharmaceuticals in the Netherlands.
Methods Three focus group interviews were conducted
with researchers, policy makers, and representatives of
pharmaceutical companies.
Results The results revealed that although all stakeholders
recognize the relevance of VOI, it is hardly used and many
barriers to the performance and use of VOI were identified.
One of these barriers is that not all uncertainties are easily
incorporated inVOI, and the resultsmaybebiased if structural
uncertainties are ignored. Furthermore, not all research
designs indicated by VOI may be feasible in practice.
Conclusions To fully embed VOI into current decision-
making processes, a threshold incremental cost-effective-
ness ratio and guidelines that clarify when and how VOI
should be performed are needed. In addition, it should be
clear to all stakeholders how the results of VOI are used in
decision making.
Key Points for Decision Makers
Value of information (VOI) is considered valuable to
guide decisions on additional research and adoption
concerning pharmaceuticals.
VOI is currently not common practice in research
and decisions concerning pharmaceuticals.
Practical guidelines are needed that indicate how to
perform VOI.
A threshold incremental cost-effectiveness ratio
(ICER) should be defined to enable VOI results to be
interpreted.
A policy framework is needed that includes criteria
of when to perform VOI, agreements on how the
results are being used and on who pays what amount
for additional research.
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1 Introduction
Decision making in healthcare is often informed by eco-
nomic evaluations, and—in many of those decisions—
uncertainty exists concerning the effectiveness and costs of
the technology under study [1]. Value of information (VOI)
is a tool that can be used to study the uncertainty associated
with a coverage decision and its implications. VOI esti-
mates the value of collecting additional data to reduce
decision uncertainty and indicates the optimal design for
additional research to obtain these data by combining the
probability and monetary consequences of an incorrect
decision [2]. To assess the value of reducing all decision
uncertainty, the expected value of perfect information
(EVPI) can be calculated. The expected value of partial
perfect information (EVPPI) is the EVPI focused on one
parameter or a subset of parameters. More extensive VOI
analyses can be used to examine the value of a certain
sample size—the expected value of sample information
(EVSI)—and to trade off this value against the costs of
additional research by calculating the expected net benefit
of sampling (ENBS) [3]. Finally, methods like real options
analysis (ROA) can assist in deciding whether to adopt a
health technology for reimbursement now (with the risk of
investing in a suboptimal therapy) or to wait for more
evidence (with the risk of withholding from patients the
optimal treatment: opportunity costs). This trade-off
becomes particularly relevant when the decision to adopt a
health technology is difficult to reverse due to high costs or
other factors [4].
In the Netherlands, a coverage with evidence develop-
ment (CED) policy for expensive intramural drugs was
implemented in the last decade. Intramural drugs are part
of the treatment carried out by or under the responsibility
of a medical specialist. This policy implied that intramural
drugs with added therapeutic value and an annual budget
impact exceeding €2.5 million should be reassessed after
4 years to decide upon their definitive adoption [5]. During
these 4 years, additional data are collected to inform the
adoption decision, mainly through the use of registries.
Within CED policy, companies were obliged to submit an
initial assessment dossier to the National Health Care
Institute in the Netherlands [Zorginstituut Nederland
(ZIN)]. It is argued that VOI can provide a useful contri-
bution in the process between initial assessment and re-
assessment, e.g. deciding upon the value of applying the
CED policy in the first place, and directing further research
[6].
Although VOI is described as best practice for handling
decision uncertainty [7], its application remains limited.
Document analysis of five CED cases published between
2013 and 2014 revealed that no VOI analyses were
performed in these five cases (see the ‘‘Appendix’’). These
five cases represent all cases published by 2014 for the
Netherlands, excluding those drugs that were used for
multiple indications. If a drug was used for multiple indi-
cations, only the most recent case was included in the
document analyses. Information concerning the perspec-
tives of stakeholders on the use of VOI is lacking [8]. The
aim of this paper is to examine (1) the potential value of
VOI within a CED policy, (2) the barriers and facilitators
of using VOI and (3) the way forward with using VOI in
the reimbursement of health technologies perceived by
different stakeholders (policy makers, researchers and
pharmaceutical companies) in the Netherlands.
2 Methods
To examine the potential value, barriers, facilitators and the
way forward with VOI, three focus groups were conducted
with stakeholders and analysed in accordance with the
COREQ (Consolidated Criteria for Reporting Qualitative
Research) guidelines [9].
2.1 Focus Groups
2.1.1 Participants
Representatives from the pharmaceutical companies, pol-
icy makers and researchers all currently involved in reim-
bursement decisions in the Netherlands were invited to
participate in homogenous focus groups in 2014. In-depth
and rich insights can be gathered, and different views
concerning VOI can be explored, via the interaction among
participants in a focus group [10]. The following partici-
pants were included: managers and market-access man-
agers from pharmaceutical companies who had submitted
an assessment or re-assessment dossier; academic and non-
academic researchers in the field of cost-effectiveness
modelling; and policy makers from ZIN, the Netherlands
Organization for Health Research and Development
(ZonMW), the Health Council of the Netherlands, and the
National Institute for Public Health and the Environment
(RIVM). Since this study is a collaborative effort between
different research groups in the Netherlands and ZIN, rel-
evant stakeholders could be identified through the profes-
sional networks of the project team and approached via
email. Three focus groups were organized in which 13
researchers, five policy makers and seven representatives
from the pharmaceutical industry participated. Familiarity
with VOI was not an inclusion criteria; therefore, the senior
researcher introduced VOI during a short presentation at
the start of the focus group.
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2.1.2 Data Collection and Analysis
All three focus groups were facilitated by the first and
second authors (JB and BR). Each focus group was mod-
erated by one senior researcher (MA, TF, MP) and started
with a short presentation on the methodology of VOI.
Subsequently, the following topics were discussed: expe-
rience with VOI, the current use of VOI, the value of VOI,
barriers and facilitators in using VOI, way forward with
VOI and its place in the decision-making process. The
members were categorized as having ‘no experience’,
‘moderate experience’ or ‘much experience’ to indicate the
level of experience with VOI. Members who had not used
the results of or performed a VOI themselves were classed
as having no experience, members who had used the results
of or performed a VOI only a few times were classed as
having moderate experience and members who had per-
formed extensive VOI analyses and used VOI repeatedly
were classed as having much experience. The focus groups
lasted 2 h and were tape recorded and transcribed verbatim.
Content analysis was used to analyse the transcripts of the
focus group [11]. First, two researchers (JB and BR) allo-
cated open codes to text fragments in the focus group
transcript; based on these codes, a report of the meetings
was developed and sent back to the participants for vali-
dation [10, 12]. The reactions of the participants were
integrated by adjusting the codes. A data matrix was
designed to visualize the codes, the related citations from
the transcripts and the categories of the three focus groups
and was discussed with all project members.
3 Results
3.1 Perspectives of Stakeholders on Value
of Information (VOI)
Although some researchers and participants from the
pharmaceutical industry had experience in performing
VOI, most of the participants expressed having limited
experience with VOI. The main results are summarized in
Table 1.
3.1.1 Value of VOI
Respondents agreed that VOI can be a relevant tool to
decide upon the need for and type of additional research,
although some respondents questioned the additional value
of VOI compared with one-way sensitivity analyses and/or
probabilistic sensitivity analysis (PSA). Respondents stated
that VOI results could be used to decide which research
designs would be necessary to reduce uncertainty. Besides
directing additional research, VOI results could also be
helpful in supporting the decision that further research is
unnecessary. Focus group participants from the pharma-
ceutical industry mentioned that VOI in combination with a
ROA could give more information concerning the required
timeframe for additional research. Furthermore, policy
makers and researchers mentioned that VOI can be helpful
in prioritizing research subjects.
3.1.2 Barriers and Facilitators
Participants in all three focus groups stated that not all
optimal research designs, indicated by VOI, are feasible.
This could be due to small patient populations or because
other drugs are used for the same indication. A randomized
controlled trial was perceived as unfeasible if the whole
patient population was using the drug under study and was
considered unethical if the necessity of the new drug was
very high. These aspects were experienced as barriers to
VOI in situations in which it is clear in advance that
specific research designs are impossible or not accepted by
policy makers as evidence. Researchers and participants
from the pharmaceutical industry therefore argued that
international data collection should be considered (espe-
cially in diseases with a low prevalence). Participants
further explained that it is not always feasible to collect
real-world data, since clinicians are often responsible for
the data collection and it can be difficult to adjust or
expand existing registries. Representatives of the pharma-
ceutical industry experienced a gap between the evidence
that is required by policy makers and the evidence that can
be generated by clinicians in real-world settings.
Various participants mentioned that VOI does not
incorporate all uncertainties. The policy makers high-
lighted that other uncertainties, such as that related to the
prescription behaviour of professionals, should also be
considered in decisions concerning additional research.
Researchers also mentioned that VOI results can provide a
distorted view of all existing uncertainties, since VOI often
disregards the structural uncertainties of a model. The
pharmaceutical industry participants further questioned
which perspective should be taken into account in VOI and
who should pay for the additional research.
Methodological and practical barriers to performing
VOI were also identified in the focus groups. Representa-
tives from pharmaceutical companies indicated that per-
forming VOI may be complex and that policy makers have
limited knowledge in interpreting the results. The feasi-
bility of performing VOI may be hindered by lack of
expertise and the fact that some VOI analyses take a long
computational time. In the focus group with the research-
ers, the different types of VOI analyses were discussed; one
researcher mentioned that performing an EVPI alone gives
insufficient information to policy makers. Further analyses,
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including the EVPPI and EVSI, are necessary to indicate
the group of parameters for which it would be worthwhile
to collect additional data and which sample size is required.
3.1.3 Way Forward with VOI
In the focus group with the pharmaceutical industry, par-
ticipants mentioned a situation in which VOI was per-
formed and presented to the decision makers, after which
the VOI results were ignored in the decision concerning
additional research. An overall impression of researchers
and the pharmaceutical company representatives is that
VOI is pointless unless the VOI results are used in decision
making concerning coverage and additional research. This
implies that policy makers should accept the results,
including if VOI indicates that additional research is not
valuable.
Although all participants agreed that VOI is not always
necessary, some policy makers expressed the fear that if
VOI is an optional extra, it will not be used in practice. The
participants of all three focus groups agreed that it is
necessary to develop criteria as to when VOI should be
performed. There was no consensus among the participants
about those criteria, apart from the general idea that VOI
should be used when uncertainty exists concerning cost
effectiveness. For example, VOI has no value in cases
where the incremental cost-effectiveness ratio (ICER) is
extremely high or extremely low and it is already clear at
the initial assessment that no substantial changes in the
ICER are expected. Individual participants mentioned that
VOI should be used for drugs with a high budget impact,
for expensive drugs and in combination with coverage and
evidence-development schemes. All participants agreed
that deciding on these criteria should be a collaborative
effort between policy makers, researchers and the phar-
maceutical industry. Researchers further indicated that it is
important to create guidelines on how VOI should be
performed. Researchers and pharmaceutical industry rep-
resentatives pointed out that a threshold ICER is necessary
to interpret the results of VOI. The pharmaceutical industry
participants stated that the maximum budget that can be
spent on additional research by each funding party (gov-
ernment, pharmaceutical industry) should be agreed upon
and taken into account when deciding upon additional
research. Furthermore, some policy makers suggested that
VOI could also be useful for directing effectiveness
Table 1 Main results from
focus groups
Themes Policy makers (n = 5) Researchers (n = 13) Pharmaceutical 
industry (n = 7)
Experience with VOI No experience (n = 2)
Moderate experience 
(n = 3)
No experience (n = 3)
Moderate experience 
(n = 6)
Much experience 
(n = 4)
No experience (n = 2)
Moderate experience 
(n = 5)
Value of using VOI VOI informs decisions about additional research
VOI is helpful in prioritising research VOI in combination 
with ROA is helpful in 
deciding on required 
timeframe for 
additional research
Barriers and facilitators Optimal research designs indicated by VOI may not be feasible
Not all uncertainties 
are incorporated in 
VOI, the decision on 
additional research is 
not only informed by 
VOI
Structural uncertainty 
is often not reflected in 
VOI. Hence, the results 
of VOI can be biased
Computational time to 
perform VOI
EVPI alone gives 
insufficient 
information
Real-world data 
collection difficult
Which perspective 
should be taken into 
account?
Limited knowledge 
concerning how to 
perform and interpret 
VOI
Way forward with VOI Criteria are needed as to when VOI should be performed
Decision making on performing VOI should be a collaborative effort
Formalize the use of 
VOI in guidance
Also use VOI in 
effectiveness research
If VOI is performed, the results should be 
incorporated when deciding upon additional 
research
A threshold ICER is necessary
Guidelines on how to 
perform VOI are 
necessary
Available budget for 
additional research 
should be agreed upon 
by all funding parties
ICER incremental cost-effectiveness ratio, ROA real options analysis, VOI value of information
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research using a threshold for minimum clinical relevant
difference.
4 Discussion
The current use of VOI in practice remains limited,
although stakeholders agree that VOI potentially has value
to inform research decisions. The participants of the focus
groups perceived that the optimal research designs indi-
cated by VOI may not be feasible in practice. Some
practical challenges for using VOI could be identified, such
as the long computational time and a lack of knowledge
concerning VOI. Furthermore, not all uncertainties that
should be regarded in health policy decision making are
easily incorporated in VOI. Guidelines that clarify how
VOI should be performed are needed. Moreover, a
threshold ICER and clarity on how the VOI results will be
used in decision making regarding adoption and additional
research are needed to fully imbed VOI in current decision
making.
VOI can support the adoption decision, because it goes
beyond reflecting the probability of making a wrong
decision by showing the consequences of such a decision
[7, 13]. In that respect, VOI can also be used in negotia-
tions for risk-sharing agreements and price arrangements.
This use of VOI appeared to be less obvious to the stake-
holders, as some respondents questioned the added value of
VOI compared with other uncertainty analyses like PSA.
Other stakeholders stated that EVPI alone was regarded as
insufficient. This does not imply that all VOI analyses are
always necessary; to decide if further research is necessary,
an EVPPI may be sufficient to prioritize groups of
parameters for further research projects [14, 15]. In gen-
eral, more clarity is needed on which VOI analyses are to
be performed in which situation.
The fact that randomized controlled trials are often
unfeasible was perceived as a barrier to perform VOI.
Particularly for less prevalent diseases, it may be desirable
to initiate international research projects, and evidence
from (ongoing) international studies could be included in
the VOI analyses. This may enable more informative reg-
istries, especially for rare diseases. However, many
authorities also require local information that is not easily
obtained from international studies (e.g. local resource use
or quality of life).
A CED policy decision should also take into consider-
ation which research designs are practically and ethically
feasible. Hence, VOI analyses should be performed for the
study designs that are considered feasible for a specific
case. In addition, the long computational time required to
perform certain analyses was mentioned as a barrier to
VOI. This point has also been raised by other researchers
[8, 14]. Participants described that VOI can be complex
and that knowledge on how to perform and interpret VOI
may be lacking. However, in the literature, new tools have
been described that simplify VOI calculations and reduce
computational challenges [16–18]. The focus group with
researchers did emphasize the importance of incorporating
structural uncertainty to obtain robust and credible VOI
assessments. Incorporating uncertainties like the uncer-
tainty concerning the choice of comparators and the
inclusion of specific events in the modelling process is
important for decision-making purposes [19, 20]. The
policy makers stressed the importance of uncertainties
unrelated to the cost-effectiveness assessment. These
uncertainties (e.g. ethical dimensions of a decision) should
be considered separately by decision makers and could be
addressed more formally in a multi-criteria decision anal-
ysis [21].
The focus groups results show that VOI is only relevant
if it is embedded in the policy window of a jurisdiction
regarding adoption decisions. The respondents stressed that
decision makers should incorporate the VOI results in the
decision-making process if these analyses are requested.
VOI outcomes can guide further research, even though
there is no fixed threshold ICER, if VOI does not vary
within the range of plausible threshold ICERs. However, if
VOI results are highly variable within a plausible range of
threshold ICERs, a fixed threshold is needed to interpret the
results of VOI and to use VOI in decision making [22]. In
the Netherlands, as well as in many other countries, this
threshold has not been formally defined [22, 23]. Different
unofficial thresholds are described in the literature, e.g. a
threshold of €20,000 per quality-adjusted life-year for
preventive interventions [24]. The focus group revealed
that guidelines are needed that clarify the decision prob-
lems for which VOI should be performed, since the
respondents agreed that VOI is not necessary in all cases.
VOI could be useful if uncertainty concerning the cost
effectiveness of expensive drugs or drugs with a high
budget impact is substantial.
The focus groups were performed in the Netherlands;
however, the insights gathered concerning the use of and
way forward with VOI might be useful for other jurisdic-
tions that apply a CED policy and a threshold ICER.
However, by examining effectiveness only (e.g. using a
threshold for minimum clinically relevant difference), VOI
could also be used in countries that do not use cost-effec-
tiveness information for coverage decisions (e.g. Germany
and the USA) [25].
To fully embed VOI in healthcare, a threshold ICER and
guidelines that clarify how VOI should be used within
research and reimbursement decisions are needed.
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Appendix: Document Analysis
See Table 2.
Table 2 Document analysis
Agalsidase alfa
(Replagal) and
agalsidase beta
(Fabrazym)
Alglucosidase alfa
(Myozyme)
Infliximab (Remicade) Omalizumab (Xolair) Ranibizumab (Lucentis)
Timings of
initial and
re-
assessment
dossier
May 2007–Jun
2011
Jul 2006–Feb 2011 Oct 2006–Feb 2011 May 2006–Mar 2011 Apr 2007–Jun 2011
Type of
economic
analysis
Cost
effectiveness
Cost utility Cost effectiveness Cost effectiveness Cost effectiveness
Comparator BSC (current
care/natural
history of the
disease
without
enzyme-
replacement
therapy)
Usual supportive
care
Cyclosporine; colectomy
with IPAA
Usual medical care BSC and photodynamic
therapy
Population All adult pts in
the Dutch
Fabry study
cohort
Children and adults
with late-onset
Pompe disease
Adult pts with moderate to
severe UC who responded
inadequately to or are
intolerant to conventional
therapy or to whom such
therapy is contraindicated
Adults and adolescents
([12 years) with severe
persistent allergic
asthma
Pts with AMD
ICER €3,282,252 Children: €232,699
Adults: €2,700,000
Infliximab vs. cyclosporine:
€23,585 (NE quadrant);
infliximab vs. colectomy
with IPAA: €15,057 (NE
quadrant)
€39,215 NE quadrant (in
initial assessment
dossier); €35,257 NE
quadrant (in re-
assessment dossier)
Lucentis was dominant in
all cases except for the
MARINA trial-based
comparison with BSC
(€40,397/QALY)
An additional ICER was
estimated (using
published evidence) vs.
bevacizumab: €53,453/
QALY, i.e. using
bevacizumab instead of
lucentis would lead to
savings of €3,658 and a
QALY loss of 0.09
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Table 2 continued
Agalsidase alfa
(Replagal) and
agalsidase beta
(Fabrazym)
Alglucosidase alfa
(Myozyme)
Infliximab (Remicade) Omalizumab (Xolair) Ranibizumab (Lucentis)
Was PSA
undertaken?
Yes (in re-
assessment
dossier)
Yes (in re-
assessment
dossier
Yes (in re-assessment
dossier)
Yes (in initial assessment
and re-assessment
dossier)
Yes (in re-assessment
dossier)
Was VOI
undertaken?
No No No No No
Additional
research
performed
Single-centre
observational
study
National
prospective
observational
study with historic
controls and data
from the IPA
survey were used
Retrospective
chart analyses of UC pts
treated with infliximab
since 2003 for which two
Dutch medical centres
(one university hospital
and one general hospital)
were included
A European multi-centre
pt outcomes registry
(experience) was
conducted for the
observational collection
of data. Retrospective
data on the medical
history and resource use
over the year prior to the
start of omalizumab
treatment were also
collected
Prospective pt registry
AMD age-related macular degeneration, BSC best supportive care, ICER incremental cost-effectiveness ratio, IPA International Pompe Asso-
ciation, IPAA ileo-pouch-anal anastomosis, NE north-east, PSA probabilistic sensitivity analysis, pt(s) patient(s), QALY quality-adjusted life-year,
UC ulcerative colitis, VOI value of information
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